CMV-associated Immunomodulation in Renal Transplant Patients
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Azonosító
- NCT06976008
- A regiszteradat frissítve
- 2025. szeptember 12.
- Eredeti leírás
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.A teljes eredeti leírásKevesebb
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.
Bevonási feltételek: st cohort :; Age > 18 years; patients with end-stage renal failure programmed for kidney transplantation with a live donor; nd cohort :; Age > 18 years; kidney transplant recipient with CMV viremia.
Kizáró feltételek: patients receiving a desensitization protocol (ABO or anti-HLA); Patients under guardianship, curatorship, legal protection; For patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :; Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion.